Ballooning 340B market reaches almost 15% of 2021 US pharma sales, IQVIA finds
The tale of a booming federal drug discount program, which pharma companies have sought to curtail, has often been told but rarely with new numbers.
Now, the drug pricing gurus at IQVIA say their latest data shows that the program, known as 340B and once designed to give massive discounts to only a select number of outpatient drugs for only a select few health care providers, has ballooned to $93.6 billion in sales in 2021, which is about 15% of the total $668.3 billion in pharma sales for the year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
